Tseng YD, Pankuch M, Mohindra P, et al. - Using a prospective, multi-institutional proton registry, mediastinal lymphoma cases managed with proton therapy were characterized as well as concordance with consensus recommendations published in 2018 by the International Lymphoma Radiation Oncology Group (ILROG) were evaluated. A review was conducted including patients suffering from lymphoma of the mediastinum who were managed exclusively with proton therapy and who offered digital imaging and communications in medicine treatment data. According to findings, typically young age with lower mediastinal involvement was evident in mediastinal lymphoma patients managed with proton therapy. Nearly all treated patients, within a prospective, multi-institutional proton registry, met the ILROG consensus recommendations about which mediastinal lymphoma cases may most benefit from proton therapy.